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Abstract Hamster fibroblasts transformed by Rous sarcoma
virus (RSV) display different metastatic potentials that are
associated with specific structural features of the v-src oncopro-
tein. This diverse metastatic activity could be due to various
tyrosine phosphorylation levels of specific src protein substrates.
To check this hypothesis, phosphorylation of the FAK and
paxillin proteins, involved in signal transduction pathways and
known as src protein substrates, was tested. It was shown that
FAK and paxillin are hyperphosphorylated in the high metastatic
cell lines as compared with the phosphotyrosine level of these
proteins found in the low metastatic cell lines. In addition, our
data confirm that v-src protein plays a direct role in paxillin
phosphorylation.
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1. Introduction
Syrian hamster ¢broblast cell lines transformed in vitro by
di¡erent stocks of the Schmidt-Ruppin D strain of Rous sar-
coma virus were shown to possess diverse metastatic activity
in vivo [1]. V-src genes both from high (HM) and low (LM)
metastatic cells had signi¢cant dissimilarities with the known
alleles of the v-src gene. In addition, certain point mutations
were revealed between v-src HM and v-src LM [2]. As a con-
sequence of these changes, the tyrosine phosphorylation of
speci¢c src substrates could be altered. To verify this possi-
bility, phosphorylation of proteins involved in integrin signal
transduction pathways and known as src targets was studied.
The comparative phosphorylation analysis of the two focal
adhesion proteins (p125FAK and paxillin), in a panel of src-
transformed cell lines displaying di¡erent metastatic potentials
is presented here.
Focal adhesion kinase p125FAK is localized in the areas of
cell attachment to components of the extracellular matrix [3,4]
and plays a role in the regulation of mature focal adhesion
contacts [5].
Paxillin is a 68-kDa protein that interacts with members of
the src family of tyrosine kinases, with several cytoskeletal
proteins and with focal adhesion kinase. This suggests a func-
tion for paxillin as a molecular adapter, responsible for the
recruitment of structural and signaling molecules to focal ad-
hesions [6,7].
FAK and paxillin were ¢rst revealed in cells transformed by
the v-src oncogene as proteins that contain a high level of
phosphotyrosine [8,9]. This ¢nding suggested that FAK and
paxillin act as substrates of v-src protein and that they might
be connected with the transforming capacity of v-src.
The initial activation of FAK is caused by its autophos-
phorylation at Tyr-397 [10]. pTyr-397 is the interaction site
between FAK and the SH2 domain of src [10,11]. Src protein
phosphorylates several tyrosine residues of FAK [12]. Consis-
tently, phosphorylation of these tyrosines results in activation
of the enzymatic activity of focal adhesion kinase [12].
Paxillin cooperates with three tyrosine kinases: FAK, src
and Csk [13^15], but the precise mechanisms responsible for
paxillin phosphorylation are not clear.
Here, we show that FAK protein and paxillin are hyper-
phosphorylated in the HM cell lines in comparison with the
phosphotyrosine level of these proteins in the LM cell lines.
Our data also suggest that the v-src protein plays a role in
paxillin phosphorylation and FAK does not seem to phos-
phorylate paxillin.
2. Materials and methods
2.1. Cell cultures
The following Syrian hamster cell lines were used: spontaneously
transformed embryo ¢broblast cell line, STHE; embryo ¢broblast cell
lines transformed in vitro with di¡erent stocks of the Schmidt-Ruppin
D strain of RSV from the Russian Cancer Research Center viral
collection: HET-SR, HET-SR1, HET-SR8; RSV-transformed embryo
¢broblast cell lines, obtained after selection in vivo of HET-SR cells ^
HET-SR-2SC [1], HET-SR-N-ras cl.6 and HET-SR-2SC-N-ras cl.34 ^
are HET-SR and HET-SR-2SC parental lines transfected by activated
N-ras oncogene [16].
Cells were grown in Dulbecco’s modi¢ed Eagle’s medium supple-
mented with 10% fetal bovine serum and 80 Wg/ml of gentamicin at
37‡C in 5% CO2.
2.2. Cell lysate preparation and immunoblotting
Cells were lysed by scraping in the following bu¡er: 20 mM Tris-
HCl, pH 7.5; 150 mM NaCl, 10 mM EDTA, 1% NP-40, 1 mM
Na3VO4, 1 mM DTT, 50 Wg/ml of PMSF. The lysates were clari¢ed
by centrifugation at 14 000Ug for 15 min at +4‡C. Protein quanti¢-
cation was done as described [17]. 20 Wg of total cell protein was
resuspended in SDS-containing sample bu¡er, separated by SDS-
10% PAGE and transferred onto nitrocellulose (BA 83, Schleicher
and Schuell). Monoclonal antibodies (mAbs) anti-p125FAK (UBI) or
anti-paxillin (Transduction Laboratories) were used to detect p125FAK
or paxillin proteins, respectively. Primary antibodies were detected by
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horseradish peroxidase-conjugated anti-mouse IgG and subsequent
enhanced chemiluminescence (Amersham).
2.3. Immunoprecipitation and immunoblotting
Anti-p125FAK or anti-paxillin mAbs mentioned above were used for
the immunoprecipitation. Puri¢ed proteins were immunoprecipitated
from 0.5 mg of cell lysate and the immune complexes were collected
with protein G-Sepharose (Sigma) and washed ¢ve times with the lysis
bu¡er. The samples were boiled in the sample bu¡er and resolved by
SDS-10% PAGE. Proteins were detected by immunoblotting with
various mAbs and phosphotyrosine was detected by immunoblotting
with the anti-phosphotyrosine-speci¢c mAb PY20 (Santa Cruz) non-
cross-reactive with phosphoserine or phosphothreonine.
2.4. Quantitative evaluation of the data
Quanti¢cation of the data was carried out with computer program
Image Quant for Windows, version 3.3. Data were analyzed with
Excel for Windows, version 7.0.
3. Results
3.1. p125FAK level and phosphorylation in high and low
metastatic cell lines
In this study, cell lines with di¡erent metastatic abilities and
various productions of v-src protein were used: low metastatic
cell lines STHE, HET-SR, HET-SR-N-ras cl.6, HET-SR-2SC-
N-ras cl.34; high metastatic cell lines HET-SR1, HET-SR8
and HET-SR-2SC. HET-SR, HET-SR1 and HET-SR8 cell
lines contained one copy of integrated RSV provirus and syn-
thesized comparable levels of v-src-speci¢c protein. HET-SR-
2SC cell line contains two copies of provirus. HET-SR-N-ras
cl.6 and HET-SR-2SC-N-ras cl.34 cell lines had reduced or no
expression of v-src gene, respectively.
It is known that migration capacity is one of the general
properties of metastatic cells. There are some reports concern-
ing p125FAK function in cell migration [18,19]. In the light of
these data, we checked the steady-state level of FAK protein
in RSV-transformed hamster ¢broblast cell lines with di¡erent
metastatic activities. It was established that these cells produce
slightly di¡erent amounts of FAK protein but we did not
observe any correlation between this protein production and
the metastatic potential of these cell lines (Fig. 1a, Table 1).
The phosphorylation level of the FAK protein, in the same
panel of src-transformed cell lines, was tested (Fig. 1b, Table
1). HET-SR1, HET-SR8 and HET-SR-2SC (Fig. 1b, lanes 3^
5, respectively) had hyperphosphorylated p125FAK on tyrosine
in comparison with the FAK phosphorylation level in the
HET-SR cell line (Fig. 1b, lane 2). Spontaneously transformed
cells STHE (Fig. 1b, lane 1), which do not express v-src, had
some FAK phosphorylation, probably as a result of FAK
autophosphorylation. Interestingly, in HET-SR-N-ras cl.6
and HET-SR-2SC-N-ras cl.34 (Fig. 1b, lanes 7 and 6, respec-
tively), where there is low or no expression of v-src gene, FAK
phosphorylation was higher than in HET-SR where the syn-
thesis of v-src protein is at a normal level. The amount of
immunoprecipitated antigen was not dependent on phospho-
rylation level of the protein (Fig. 1c).
3.2. Paxillin level and phosphorylation in high and low
metastatic cell lines
Paxillin is a focal adhesion component. It interacts with
many proteins, some of which are tyrosine kinases but, until
now, the tyrosine kinase responsible for phosphorylation of
paxillin has remained unknown.
According to Western blot analysis, paxillin was produced
in all the v-src-transformed cell lines at approximately the
same levels. In spontaneously transformed STHE cells, the
amount of this protein was reduced (Fig. 2a, Table 1).
It was suggested earlier that src protein kinase is essential
for paxillin phosphorylation [21]. The tyrosine phosphoryl-
ation of paxillin in v-src-transformed cell lines with di¡erent
levels of oncoprotein production and di¡erent metastatic
properties was studied (Fig. 2b, Table 1).
In the high metastatic cell lines HET-SR1, HET-SR8 and
HET-SR-2SC, we found that paxillin was hyperphosphoryl-
Table 1
















HSR low 1.00 1.00 1.00 1.00 1.00
HSR1 high 1.50 0.85 1.77 0.90 3.08
HSR8 high 1.37 1.13 2.28 1.10 6.30
HSR-2SC high 1.30 1.35 1.60 1.39 3.25
HET-SR-N-ras cl.6 low 0.22 1.47 1.29 1.36 1.43
HSR-2SC-N-ras cl.34 low 0.00 1.57 1.17 1.39 0.00
STHE low 0.00 0.74 0.84 0.55 0.00
aLow: metastatic nodules were usually not identi¢ed after inoculation of hamsters; high: between 70 and 200 metastatic nodules in the lung of
inoculated hamsters.
bRelative phosphorylation of FAK or paxillin normalized to the production of these proteins in corresponding cell lines.
Fig. 1. Immunoblot analysis of FAK protein (a) and its phosphoryl-
ation (b) in src-transformed hamster cell lines. a: 20 Wg of total cell
lysate was immunoblotted with anti-FAK antibodies. b: FAK was
immunoprecipitated from total cell lysates, and the immune com-
plexes were immunoblotted with antibodies recognizing phosphoty-
rosine. c: Phosphotyrosine blot was stripped and reprobed with
anti-FAK antibodies to visualize the quantity of FAK protein. The
panel of cell lines was: STHE (1); HET-SR (2); HET-SR1 (3);
HET-SR8 (4); HET-SR-2SC (5); HET-SR-2SC-N-ras cl.34 (6); and
HET-SR-N-ras cl.6 (7).
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ated on tyrosine (Fig. 2b, lanes 3^5, respectively). Paxillin
phosphorylation was not detectable in STHE (Fig. 2b, lane
1) and HET-SR-2SC-N-ras cl.34 (Fig. 2b, lane 7) cell lines,
although these cells contain substantial amounts of paxillin
protein (Fig. 2a).
Thus, in the majority of src-transformed cells, the phos-
phorylation of paxillin is correlated with the level of v-src
protein.
4. Discussion
Transformation of cells by active variants of src protein
leads to a pronounced increase in tyrosine phosphorylation
of a number of cellular proteins, including several signal
transducing factors. Here, we report a novel attempt to study
the production and phosphorylation of p125FAK and paxillin,
involved in the integrin signal transducing pathway. We took
advantage of the described model system of hamster cells
transformed by two isoforms of v-src oncogene [2]. The panel
of analyzed cells includes lines with di¡erent metastatic po-
tentials in vivo and various levels of v-src protein.
It is known that FAK plays a role in cell motility and that
overexpression of this kinase increases cell migration on ¢bro-
nectin [18,22]. We have studied the steady-state level of FAK
in RSV-transformed hamster ¢broblasts to reveal any possible
correlation existing between FAK synthesis and metastatic
properties of the cells. It has been established that these cells
produce di¡erent amounts of FAK protein. However, an as-
sociation of this parameter with the metastatic status of the
cell lines could not be detected (Table 1).
A correlation was found between the metastatic phenotype
of cells and the tyrosine phosphorylation level of p125FAK. In
highly metastatic cell lines, this protein was 1.6^2.2 times
more phosphorylated than in the low metastatic cell lines
(Table 1).
There is strong evidence concerning the role of src in the
phosphorylation of FAK [12]. p125FAK phosphotyrosine-397
(the site of autophosphorylation) is the interaction site be-
tween FAK and the SH2 domain of src [10,11]. Src phospho-
rylates FAK on Tyr-576 and Tyr-577, localized in the FAK
kinase domain, and on Tyr-407 [12] and Tyr-925 [23]. Accord-
ing to our data, v-src is probably not the main factor respon-
sible for FAK phosphorylation, at least in the transformed
cells we studied. For instance, in the cells over-transfected
by N-ras, leading to a reduction or an elimination of v-src
expression (HET-SR-N-ras cl.6 and HET-SR-2SC-N-ras
cl.34), there is no association with signi¢cant loss of FAK
phosphotyrosine. We suggest that in these clones the phos-
phorylation of FAK is associated with an increased steady-
state level of cellular src [24] and/or appears to be associated
with the e¡ect of constitutively activated N-ras.
The amount of paxillin in the analyzed cells was not con-
nected with their metastatic potential in vivo (Table 1), but a
signi¢cant correlation was found between the level of tyrosine
phosphorylation of this protein and the biological properties
of cell lines. In all highly metastatic cell lines, paxillin was 3^6
times more phosphorylated than in the low metastatic HET-
SR cells (Table 1).
The mechanisms involved in paxillin phosphorylation are
not clear. Previously, it was demonstrated that at least three
tyrosine kinases are able to phosphorylate paxillin, namely
p125FAK, pp60src and Csk [25]. Our data suggest that in the
cell lines we studied, the phosphorylation of paxillin is due to
v-src (this is not the case for FAK in these cell lines). In cells
with suppressed v-src gene expression (HET-SR-2SC-N-ras
cl.34) tyrosine phosphorylation of paxillin was not detected
(Fig. 2b, Table 1). We suggest that in the analyzed cell lines,
FAK is not essential for paxillin phosphorylation, because
this protein remains unphosphorylated in cells containing a
signi¢cant amount of p125FAK.
In the study presented in this paper, we surmised that alter-
ations in the phosphorylation level of target proteins, modu-
lating some signal transduction processes, might exert in£u-
ence on many di¡erent biological properties of the cells, such
as metastatic activity.
The comparative analysis of downstream components, in-
teracting with src in signal transducing pathways, might help
to understand some of the molecular events underlying meta-
static processes.
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